leisure time -WSS

leisure time

author：knowledge 2025-09-02 08:20:10 - browse：2

WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

WSS

Listen: Who gets the credit for GLP

Disclosing genetic information: not as worrisome as once feared

What would happen to your eyes if you looked at the solar eclipse?

Do masks work? RCTs can't tell us

WATCH: Why do fingernails fall off when they're damaged?

FDA advisers vote against ALS treatment from BrainStorm

knowledge

leisure time

explore

Psychedelics group wrestles with new pharma identity

Biogen shutters digital health group, ends Apple study, in cost cutting move

What does generative AI mean for health care? We asked experts

Address the ethical violations that led to 'Three Identical Strangers'

How one medical school became remarkably diverse

Inequities make cancer less preventable for women: report

Continuity nursing helped my family in our darkest PICU moments

Gene therapy has helped boys walk. Can scientists keep it that way?

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

The science behind Janet Jackson's pregnancy at 49

Death of patient in Alzheimer’s trial raises question of possible risks

Sudafed saga points to U.S. issues with evaluating older drugs

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Sudafed saga points to U.S. issues with evaluating older drugs

knowledge

hotspot

knowledge

Wikipedia